Mobile website
Archive > Volume 31 Issue 8 > 2024,31(8):815-820. DOI:10.3872/j.issn.1007-385X.2024.08.009 Prev Next
Clinical Research
Clinical efficacy of DC combined with CIK in treating locally advanced or advanced pancreatic cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the clinical efficacy of dendritic cells (DC) combined with cytokine-induced killer cells (CIK) in the treatment of locally advanced or advanced pancreatic cancer. Methods: A retrospective analysis was conducted on the clinical data of 156 patients with locally advanced or advanced pancreatic cancer who underwent autologous DC combined with CIK treatment in the Oncology Department of the Eastern Theater Command General Hospital from November 2011 to December 2023. Changes in serum tumor markers, lymphocyte subsets, cytokine levels, adverse reactions, short-term efficacy, and long-term efficacy before and after treatment were statistically analyzed. Results: Among the 156 pancreatic cancer patients, 92 underwent imaging examinations before and after treatment, with results showing no CR (complete remission), no PR (partial remission), 42 cases of SD (stable disease), and 50 cases of PD (progressive disease). The objective remission rate (ORR) was 0%, and the disease control rate (DCR) was 45.65%. There was no significant difference in peripheral blood CA199 levels before and after treatment, but 19 patients showed a reduction of more than 20% after treatment. No statistical differences were observed in CD3+ , CD4+ , CD8+ , CD56+ , CD25+ peripheral blood lymphocyte subsets levels and CD4+ /CD8+ T cell ratio before and after treatment (all P>0.05). However, the average levels of IL-2 and IFN-γ in peripheral blood of patients were significantly increased after treatment (all PP>0.05). The median overall survival (mOS) of the 156 patients was 8.53 months, with 1-year, 2-year, and 3-year cumulative survival rates of 39%, 15%, and 15%, respectively. No 5-year survival data were available for follow-up. No severe adverse reactions occurred during the treatment. Conclusion: DC-CIK therapy can induce anti-tumor immune responses in patients with locally advanced and advanced pancreatic cancer, achieving certain objective efficacy and potentially prolonging patient survival.
Keywords:
Project Supported:
Clc Number:
